The Hepatitis C drugs in development market research report provides comprehensive information on the therapeutics under development for Hepatitis C, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hepatitis C. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hepatitis C and features dormant and discontinued products.

GlobalData tracks 113 drugs in development for Hepatitis C by 94 companies/universities/institutes. The top development phase for Hepatitis C is discovery with 42 drugs in that stage. The Hepatitis C pipeline has 82 drugs in development by companies and 31 by universities/ institutes. Some of the companies in the Hepatitis C pipeline products market are: Merck, Cocrystal Pharma and HEC Pharma.

The key targets in the Hepatitis C pipeline products market include Nonstructural Protein 5A (NS5A), NS5B (Nonstructural Protein 5B Polymerase or EC, and Hepatitis C Virus Envelope Protein E2.

The key mechanisms of action in the Hepatitis C pipeline product include Nonstructural Protein 5A (NS5A) Inhibitor with 13 drugs in Pre-Registration. The Hepatitis C pipeline products include nine routes of administration with the top ROA being Oral and 18 key molecule types in the Hepatitis C pipeline products market including Small Molecule, and Subunit Vaccine.

Hepatitis C overview

Hepatitis C is a contagious viral infection affecting the liver. It spreads on contact with infected blood. It may be a mild condition or may be chronic, leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea, and vomiting. The predisposing factors of hepatitis C include dialysis, organ transplant, and blood transfusion. The offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.

For a complete picture of Hepatitis C’s pipeline drug market, buy the report here.

This content was updated on 25 January 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.